Through 2019, increased generic erosion of key drugs will cause a precipitous $2.3 billion decline in the bipolar disorder market

The increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis' Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar disorder drug market over the next decade, warns advisory firm Decision Resources.

The Pharmacor 2010 findings from the topic entitled Bipolar Disorder reveal that although patient share for atypical antipsychotics will increase through 2019, particularly in France, Germany, Italy, Spain, the UK and Japan, sales of atypical antipsychotics will decline significantly over the forecast period owing to the generic erosion of key agents such as AstraZeneca/Astellas' Seroquel (quetiapine) and Seroquel XR, Eli Lilly's Zyprexa (olanzapine), Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify (aripiprazole) and Pfizer's Geodon (ziprasidone).

Dainippon Sumitomo/Sepracor's lurasidone will become a market leader in 2019